🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. Bufei Yishen granule

    Henan University of Traditional Chinese Medicine

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial
  2. Bupivacaine

    United Therapeutics Europe Ltd

    Postoperative Pain

    phase 3 small molecule active

    1 trial
  3. Bupivacaine HCl

    Pacira Ireland Limited

    Hemorrhoids

    phase 3 small molecule completed

    1 trial
  4. Bupivacaine Liposome Injection

    United Therapeutics Europe Ltd

    Osteoarthritis

    phase 3 small molecule terminated

    1 trial
  5. Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 3 small molecule completed

    2 trials
  6. Buprenorphine +OTP

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Addiction

    phase 3 small molecule completed

    1 trial
  7. Buprenorphine/naloxone

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 3 small molecule completed

    2 trials
  8. Busulfan (BU)

    The First People's Hospital of Lianyungang

    Primary Central Nervous System Lymphoma

    phase 3 small molecule active

    1 trial
  9. C1 esterase inhibitor [human] (C1INH-nf)

    Takeda

    Hereditary Angioedema

    phase 3 mab completed

    5 trials
  10. C1 esterase inhibitor [human] liquid

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial
  11. CAPECITABINE, DS-8201a, INFLIXIMAB, CISPLATIN, MYCOPHENOLATE MOFETIL, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate for solution for infusion, FLUOROURACIL, Rilvegostomig, OXALIPLATIN, TRASTUZUMAB

    AstraZeneca AB

    HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

    phase 3 small molecule active

    1 trial
  12. CAPECITABINE, PACLITAXEL, CAPECITABINE, DS-8201a, Abraxane 5 mg/ml powder for dispersion for infusion.

    AstraZeneca AB

    HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.

    phase 3 small molecule active

    1 trial
  13. CARBOPLATIN , FLUOROURACIL , JNJ-61186372, CISPLATIN , PEMBROLIZUMAB

    Janssen-Cilag International N.V.

    Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial
  14. CARBOPLATIN, CARBOPLATIN, DS-8201a, PEMETREXED, CISPLATIN, PEMBROLIZUMAB

    Daiichi Sankyo

    Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  15. CARBOPLATIN, CARBOPLATIN, IPILIMUMAB, PEMETREXED, CISPLATIN, INFLIXIMAB, PEMETREXED, Mycofit, 250 mg, kapsułki twarde, NIVOLUMAB, volrustomig

    AstraZeneca AB

    Unresectable Pleural Mesothelioma

    phase 3 small molecule active

    1 trial
  16. CARBOPLATIN, CISPLATIN, PEMBROLIZUMAB, PEMETREXED, DS-8201a, PEMETREXED

    AstraZeneca AB

    Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations

    phase 3 small molecule active

    1 trial
  17. CARBOPLATIN, GEMCITABINE, PEMBROLIZUMAB, CISPLATIN, BT8009, AVELUMAB

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial
  18. CARBOPLATIN, GEMCITABINE, PEMETREXED, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CISPLATIN, Abraxane 5 mg/ml powder for dispersion for infusion., RO 749-9790/F02-02

    Hoffmann-La Roche

    RET fusion−positive, metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  19. CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride

    Sarepta Therapeutics

    Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.

    phase 3 small molecule active

    1 trial
  20. CBD 100 mg/mL Oral Solution

    COGNITION THERAPEUTICS INC

    Treatment Resistant Psychosis

    phase 3 small molecule active

    1 trial
  21. CBD 100 mg/mL Oral Solution

    COGNITION THERAPEUTICS INC

    Psychosis

    phase 3 small molecule active

    1 trial
  22. CEFTAZIDIME, PIPERACILLIN, CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE, CEFTAZIDIME, CEFEPIME , CEFEPIME, MEROPENEM , TAZOBACTAM, TAZOBACTAM, MEROPENEM, AMIKACIN , AMIKACIN, PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE AND BETA-LACTAMASE INHIBITOR , AVIBACTAM, CEFTAZIDIME

    Pari Pharma GmbH

    antibiotic therapy in Sepsis

    phase 3 small molecule active

    1 trial
  23. CELLULOSE, MICROCRYSTALLINE, OSELTAMIVIR , DEXAMETHASONE

    The George Institute

    Severe Influenza

    phase 3 small molecule active

    1 trial
  24. CEP-33457

    Teva Pharma GmbH

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources